<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Hormone refractory</title>
	<atom:link href="http://www.psa-rising.com/blog/category/pca/hormone-refractory/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Tue, 16 Aug 2011 09:39:00 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>New Pathway to Potential Therapies for Advanced Prostate Cancer</title>
		<link>http://www.psa-rising.com/blog/2011/07/new-pathway-to-potential-therapies-for-advanced-prostate-cancer/</link>
		<comments>http://www.psa-rising.com/blog/2011/07/new-pathway-to-potential-therapies-for-advanced-prostate-cancer/#comments</comments>
		<pubDate>Wed, 27 Jul 2011 19:47:24 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Castration Resistant]]></category>
		<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Hormone refractory]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Avodart]]></category>
		<category><![CDATA[CRPC]]></category>
		<category><![CDATA[SRD5A]]></category>
		<category><![CDATA[Zytiga]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2402</guid>
		<description><![CDATA[PSA Rising /DALLAS/ – July 25, 2011 – UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than previously was thought. &#8220;We have recently discovered that castration resistant prostate cancer (CRPC) is unexpectedly driven by dihydrotestosterone synthesis [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2011/07/new-pathway-to-potential-therapies-for-advanced-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Provenge available for men with advanced prostate cancer at Roswell Park</title>
		<link>http://www.psa-rising.com/blog/2011/02/provenge-available-for-men-with-advanced-pca-at-roswell-park/</link>
		<comments>http://www.psa-rising.com/blog/2011/02/provenge-available-for-men-with-advanced-pca-at-roswell-park/#comments</comments>
		<pubDate>Wed, 16 Feb 2011 00:39:59 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Hormone refractory]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Add new tag]]></category>
		<category><![CDATA[Advanced PCa]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2368</guid>
		<description><![CDATA[February 7 2011, BUFFALO, NY — The nation’s first FDA-approved cancer treatment vaccine, Provenge (sipuleucel-T), is being offered for the first time in Western New York at Roswell Park Cancer Institute (RPCI). The vaccine is designed for men with advanced prostate cancer who have limited treatment options and who meet eligibility requirements. “It’s the first [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2011/02/provenge-available-for-men-with-advanced-pca-at-roswell-park/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8220;Complete Remission&#8221; in Hormone Refractory Prostate Cancer</title>
		<link>http://www.psa-rising.com/blog/2007/06/complete-remission-in-hormone-refractory-prostate-cancer/</link>
		<comments>http://www.psa-rising.com/blog/2007/06/complete-remission-in-hormone-refractory-prostate-cancer/#comments</comments>
		<pubDate>Fri, 01 Jun 2007 22:43:38 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Hormone refractory]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[capecitabine]]></category>
		<category><![CDATA[etoricoxib]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/06/01/complete-remission-in-hormone-refractory-prostate-cancer</guid>
		<description><![CDATA[From ASCO annual general meeting, 2007, comes this abstract of a study by A. Reichle, B. Walter, A. Berand, M. Vogelhuber, K. Bross, J. Wilke, W. Wieland, R. Andreesen, S. Rogenhofer. Background: The present multi-centre phase II study was designed to support the hypothesis that networking agents binding to ubiquitous accessible targets in metastatic hormone-refractory [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/06/complete-remission-in-hormone-refractory-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cougar&#8217;s CB7630 (abiraterone acetate) trial results</title>
		<link>http://www.psa-rising.com/blog/2007/05/cougars-cb7630-abiraterone-acetate-trial-results/</link>
		<comments>http://www.psa-rising.com/blog/2007/05/cougars-cb7630-abiraterone-acetate-trial-results/#comments</comments>
		<pubDate>Thu, 31 May 2007 14:44:51 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[CB7630 (abiraterone acetate)-Cougar]]></category>
		<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Hormonal-ADT]]></category>
		<category><![CDATA[Hormone refractory]]></category>
		<category><![CDATA[Prostate Cancer]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/05/31/cougars-cb7630-abiraterone-acetate-trial-results</guid>
		<description><![CDATA[Cougar Biotechnology&#8217;s once-daily oral drug CB7630 (abiraterone acetate), based on recently announced trial results, appears o have some efficacy at two stages of the standard treatment path for androgen independent prostate cancer &#8212; either before or after chemotherapy. A UK Phase I/II trial of CB7630 reports positive signs among a small number of patients enrolled [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/05/cougars-cb7630-abiraterone-acetate-trial-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

